home / stock / nuro / nuro quote
Last: | $4.19 |
---|---|
Change Percent: | 1.7% |
Open: | $4.05 |
Close: | $4.19 |
High: | $4.19 |
Low: | $3.85 |
Volume: | 33,674 |
Last Trade Date Time: | 10/08/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$4.19 | $4.05 | $4.19 | $4.19 | $3.85 | 33,674 | 10-08-2024 |
$4.12 | $4.09 | $4.12 | $4.2 | $4.09 | 8,855 | 10-07-2024 |
$4.1384 | $4.155 | $4.1384 | $4.155 | $4.0913 | 1,617 | 10-04-2024 |
$4.0728 | $4.225 | $4.0728 | $4.25 | $4.0728 | 6,755 | 10-03-2024 |
$4.2 | $4.1 | $4.2 | $4.239 | $3.98 | 10,649 | 10-02-2024 |
$4.18 | $3.93 | $4.18 | $4.2 | $3.93 | 11,060 | 10-01-2024 |
$3.97 | $4.06 | $3.97 | $4.19 | $3.97 | 16,766 | 09-30-2024 |
$3.93 | $4.1842 | $3.93 | $4.1842 | $3.86 | 12,402 | 09-27-2024 |
$4 | $3.9628 | $4 | $4.2471 | $3.89 | 33,469 | 09-26-2024 |
$4.1 | $3.9224 | $4.1 | $4.1636 | $3.87 | 27,017 | 09-25-2024 |
$3.89 | $4.008 | $3.89 | $4.225 | $3.89 | 27,507 | 09-24-2024 |
$4.02 | $3.98 | $4.02 | $4.27 | $3.98 | 43,829 | 09-23-2024 |
$3.93 | $3.8 | $3.93 | $3.93 | $3.65 | 18,363 | 09-20-2024 |
$3.82 | $3.8115 | $3.82 | $3.9399 | $3.65 | 15,713 | 09-19-2024 |
$3.81 | $4.0502 | $3.81 | $4.18 | $3.6859 | 50,509 | 09-18-2024 |
$4.05 | $3.985 | $4.05 | $4.13 | $3.78 | 19,101 | 09-17-2024 |
$4.02 | $3.7972 | $4.02 | $4.0847 | $3.7972 | 12,774 | 09-16-2024 |
$4 | $4.05 | $4 | $4.05 | $3.83 | 15,797 | 09-13-2024 |
$4.05 | $3.96 | $4.05 | $4.1123 | $3.96 | 32,706 | 09-12-2024 |
$3.9899 | $3.86 | $3.9899 | $3.9899 | $3.86 | 13,172 | 09-11-2024 |
News, Short Squeeze, Breakout and More Instantly...
WOBURN, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today for the purpose of clarity, reiterated that the Company is engaged in a review of strategic alternatives. In February of this year, the Company announced that it had initiated a review of strategic optio...
WOBURN, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and six months ended June 30, 2024. The Company's mission is to reduce the impact of neurological disorders and pain syndromes through innovative non-...